Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer
Evidence for efficacy is based on the results from the ECHELON-3 study
Biomarker analyses from the CheckMate 649 study
Findings from the MANIFEST-2 study
Findings from the TROPiCS-04 study
New indication concerns the management of adult patients with unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer
Evidence for efficacy is based on the results from the ReNeu study
Findings from machine learning-based and population-level electronic health record data-based emulation of landmark phase III randomised clinical trials in oncology
Findings from a population-based study
Findings from the Beamion LUNG-1 study
The combination is indicated for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma
Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
